Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03766425
Other study ID # KE-0254/133/2017
Secondary ID
Status Completed
Phase Early Phase 1
First received
Last updated
Start date June 14, 2017
Est. completion date July 31, 2019

Study information

Verified date October 2023
Source Medical University of Lublin
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Comparison of efficacy and safety of Mitomycin and Aflibercept used to support primary trabeculectomy - a prospective, randomized trial in patients with open-angle glaucoma undergoing surgery.


Description:

Glaucoma is a neurodegenerative disease characterized by progressive dying of retinal ganglion cells, axonal loss and damage to the optic nerve. This leads to a gradual loss of the visual field, and in the final stage to blindness. High intraocular pressure is considered to be the main risk factor for glaucomatous neuropathy. In the treatment we use pharmacological therapies and surgical treatment. The trabeculectomy has been the golden standard for the treatment of glaucoma for many years. This procedure consisting in the creation of a filtering bleb, which allows drainage of aqueous humor from within the eye to underneath the conjunctiva where it is absorbed. in addition to the surgery, anti-proliferative substances play a significant role in suppressing the physiological healing process. Bleb insufficiency observed in the postoperative period results to a large extent from progressive scarring of the follicle, which is responsible for excessive fibroblast proliferation and subconjunctival fibrosis. Mitomycin is an antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional alkylating agents causing cross-linking of DNA and inhibition of DNA synthesis. Its properties cause that mitomycin is now a popular medicine used to support trabeculectomy, with proven effectiveness of inhibiting the unwanted healing process of the fistula, and thus extend its period of its proper functioning. Aflibercept is an inhibitor of vascular endothelial growth factor (VEGF). Its properties cause inhibition of the pathological process of formation of new vessels and their excessive permeability, as well as reduction of leukocyte infiltration and inflammation. The aim of the research: Comparison of the effectiveness of primary trabeculectomy in patients with open angle glaucoma supported with Eylea (Aflibercept) compared to the group of patients treated with mitomycin. Materials and methods: The research conducted at the Department of Glaucoma Diagnostics and Microsurgery in Medical University of Lublin will include patients treated with antiproliferative substances and trabeculectomy. Two groups of patients will participate in the study: Group I - patients qualified for mitomycin trabeculectomy Group II - patients qualified for Eylea assisted trabeculectomy (Aflibercept) Mitomycin will be administered in the first group of patients during an operation at a dose of 0.3mg / ml for 3 minutes on a soaked sponge. Aflibercept will be applied intraoperatively in a dose of of 0.05 ml (40 mg / ml) subconjunctival and one week after surgery in the same dose. Criteria for inclusion: 1. Open angle glaucoma or capsular glaucoma. 2. Patient's age> 40 years 3. Local treatment ineffective due to: 1. intraocular pressure more than 21mmHg with maximum pharmacological therapy (using B-blocker + carbonic anhydrase + prostaglandins) or 2. intolerance to topical treatment or 3. progression in the visual field examination (assessed on the basis of MD, PSD). 4. Lack of previous ophthalmological surgical interventions. 5. No previous laser gonioplasty. 6. No previous laser trabeculoplasty or laser trabeculoplasty performed for more than a year. Exclusion criteria: 1. Patient with angle-closure glaucoma or secondary glaucoma (except for glaucoma in the course of pseudoexfoliation syndrome). 2. One-eye patient. 3. A patient with pseudophakia or aphakia. 4. Patient after previous ophthalmic procedures (phacoemulsification with intraocular lens implantation, traditional pars plana vitrectomy, keratoplasty). 5. A patient diagnosed or suspected of having uveitis or intraocular inflammation. 6. Any corneal abnormalities or other conditions that make it impossible to reliably test with an applanation tonometer in the treated eye, including earlier refractive surgery of the eye The efficacy of surgery in both groups will be assessed at subsequent postoperative controls based on the following diagnostic tests: - Visual acuity examination; - Intraocular pressure examination; - Evaluation of the filtering bleb in the slit lamp; - A photo of the filtering bleb; - Optical coherence tomography of the filtration bleb; - Visual field; - Study of corneal endothelial cell density.


Recruitment information / eligibility

Status Completed
Enrollment 64
Est. completion date July 31, 2019
Est. primary completion date July 31, 2019
Accepts healthy volunteers No
Gender All
Age group 40 Years and older
Eligibility Inclusion Criteria: 1. Primary open-angle glaucoma or capsular glaucoma. 2. Patient's age: over 40 years, no sex preference; 3. Local treatment ineffective due to: 1. Intraocular pressure above 21mmHg at maximum pharmacological therapy (using ß-blocker + carbonic anhydrase inhibitor + prostaglandins) or 2. Intolerance to topical treatment or 3. Progression in visual field examination 4. Lack of previous ophthalmological surgical interventions. 5. Lack of previously performed laser gonioplasty. 6. No laser trabeculoplasty or laser trabeculoplasty performed for more than a year. Exclusion Criteria: 1. Patient with primary closed-angle glaucoma or secondary glaucoma (except for glaucoma in the course of pseudoexfoliation syndrome). 2. One-eye patient. 3. Patient with aphakia. 4. Patient after previous ophthalmic procedures (cataract removal by phacoemulsification with an implant of an intraocular lens, vitrectomy by pars plana, keratoplasty). 5. A patient diagnosed or suspected of having uveitis or intraocular inflammation. 6. Any corneal abnormalities or other conditions that prevent reliable testing with an applanation device in the treated eye, including earlier refractive surgery of the eye.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Aflibercept
subconjunctival injection
Mitomycin
subconjunctival injection

Locations

Country Name City State
Poland Medical University of Lublin Lublin Lubelskie

Sponsors (1)

Lead Sponsor Collaborator
Medical University of Lublin

Country where clinical trial is conducted

Poland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Effectiveness of aflibercept and mitomycin on the morphology of the bleb; Rating the bleb in The Indiana Bleb Appearance Grading Scale, describing bleb height, extent, vascularity, and leakage with the Seidel test. 1 year
Primary Effectiveness of aflibercept and mitomycin on the function of the bleb; Measurement of intraocular pressure (Goldmann applanation tonometer) and taking a photo of a bleb. 1 year
Secondary Impact of tested substances on visual acuity after surgery Examination of a visual acuity 1 week after operation as well as 1 month, 3 months, 6 months, 12 months 1 year
Secondary The influence of aflibercept and mitomycin on corneal endothelial cell density after surgery Examination of the corneal endothelial cell density before the surgery as well as 6 months and 12 months after surgery 1 year
Secondary Impact of used substances on visual field parameters Examination of a visual field in SITA (Swedish Interactive Testing Algorithm) FAST strategy before the surgery and 12 months after surgery 1 year
Secondary Frequencies and type of possible complications. observing and recording all complications and side effects in both groups of patients 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT05414994 - Assessment of the Ocular Microbiome in Health and Disease
Active, not recruiting NCT04271709 - Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT) N/A
Completed NCT02811692 - Study for Collection of Aflibercept Data in Routine Practice
Recruiting NCT06045299 - Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Presbyopia Phase 3
Recruiting NCT01521065 - An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration Phase 2
Completed NCT04799704 - Tear Film SARS-nCoV-2 Detection in Symptomatic and Pauci-symptomatic Patients.
Recruiting NCT05876689 - Swept Source OCT Imaging With the DREAM VG-OCT
Active, not recruiting NCT04123626 - A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene Phase 1/Phase 2
Recruiting NCT04150432 - Correlation Between Exhaled Propofol Concentration With Plasma Concentration in Children N/A
Not yet recruiting NCT05550740 - Repeated Low-Level Red-Light Therapy for Shortening Axial Length N/A
Completed NCT02332343 - Sparing of the Fovea in Geographic Atrophy Progression N/A
Completed NCT01727973 - Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy Phase 1/Phase 2
Terminated NCT01225146 - Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2) Phase 1
Completed NCT00333203 - Next Generation Ophthalmic Irrigating Solution Posterior Segment Study Phase 3
Not yet recruiting NCT05565547 - Multimodal Equipment for Teleophthalmology Assessment (META)
Recruiting NCT05158699 - Effectiveness of Periocular Drug Injection in CATaract Surgery Phase 3
Recruiting NCT06451172 - Novel Antisense Oligonucleotide Eye Drops for Treating Antibiotic-Resistant Bacterial Keratitis Early Phase 1
Recruiting NCT06112340 - A Phase 2b Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) Phase 2/Phase 3
Completed NCT05211089 - Manual Versus Automated Choroidal Thickness Measurements Using Swept-source Anterior Segment OCT
Not yet recruiting NCT06070467 - Holistic Mixed Approaches to Capture the Real Life of Children With Rare Eye Diseases